-
Posted by
Two Blokes May 15 -
Filed in
Stock
-
1 view
Novo Nordisk's stock has declined 55% from its all-time high, but the company continues to report strong quarterly results with significant revenue and profit growth. Despite slowing growth rates and revised guidance, NVO's rich pipeline and strategic acquisitions position it for sustained high growth, particularly in diabetes, GLP-1, and obesity care. The company's current product portfolio is well-protected by patents until at least 2030, ensuring stable revenue from key products like Wegovy and Ozempic.
